4,901 trials
Congenital Muscular Dystrophy
Primary: Pharmacokinetic Profile of Omigapil:Maximum Observed Plasma Concentration (Cmax) of Omigapil — 1.05; 4.75; 2.15; 3.27 ng/mL
Advanced Solid Tumors · Relapsed/Refractory Lymphoma
Primary: Cmax: Maximum Observed Concentration of Alisertib in Presence and Absence of Itraconazole in Part A — 1060.3; 1002.8 nmol/L
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) — 0; 0; 0; 0 Participants
Common Cold
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) — 0; 0; 0 Participants
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of L-Praziquantel (L-PZQ) — 441.53; 547.41; 460.25 Hour*nanogram…
HIV Infections
Primary: Changes in Intracellular Emtricitabine Triphosphate (FTC-TP) — 0; 3380; 2580; 6470 fmol/1000000 PBMC
Autoimmune Diseases
Primary: Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs) — 0; 1; 0; 0 Participants
Diabetes Type I · Diabetes Type II
Primary: Percentage of Wound Area Reduction Compared to Baseline — 87 percentage of wound closure
Alzheimer's Disease
Primary: Number of Participants With Clinically Significant Effects (Adverse Events) — 0; 0; 0; 0 Participants
Adult Onset Rheumatoid Arthritis
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 13; 3; 7; 6 Participants
Healthy Volunteers
Primary: Percentage of Urinary and Fecal Excretion of LY2886721 Radioactivity Over Time — 85.7; 8.86 percentage of radioactive dose
Female Sexual Dysfunction
Primary: Bioavailability (AUC0-t) of Total Testosterone Through Pharmacokinetic (PK) Profiles — 223.981; 328.002; 834.391; 553.325 ng*h/dL
Renal Impairment
Primary: Maximum Plasma Concentration (Cmax) of Total Telotristat Ethyl, LP-778902 and LP-951757 — 3.81; 4.94; 533; 759 ng/mL
Advanced Cancer
Primary: Recommended Phase 2 Dose: Maximum Tolerated Dose — 400 milligrams (mg)
Solid Tumours
Primary: Maximum Plasma Concentration (Cmax) — 7.32; 8.25; 6.40 μg/mL